Swedish Orphan Biovitrum ABSWOBY 67 OCF Yield % is 4.92 as of Jun. 24, 2026, which is 23% below its 10-year median of 6.41. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 58.01% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Swedish Orphan Biovitrum AB OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Swedish Orphan Biovitrum AB OCF Yield % Related Terms
Swedish Orphan Biovitrum AB OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a OCF Yield % of 4.92 as of Jun. 24, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 23% below median its historical median of 6.41. Over the past decade, Swedish Orphan Biovitrum AB's OCF Yield % has ranged from 1.01 to 11.96. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #422 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 42%.
Is Swedish Orphan Biovitrum AB's OCF Yield % too high?
Swedish Orphan Biovitrum AB's current OCF Yield % of 4.92 is 23% below median its 10-year median of 6.41. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 11.96. The Drug Manufacturers industry median OCF Yield % is 3.54. Swedish Orphan Biovitrum AB's value of 4.92 is 39% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #422 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #422 out of 1005 companies for OCF Yield %. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median OCF Yield % is 3.54. Swedish Orphan Biovitrum AB's value of 4.92 is 39% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own OCF Yield % has ranged from 1.01 to 11.96 over the past decade. While the company's 10-year median is 6.41 vs. the industry median of 3.54, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.54, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current OCF Yield % of 4.92 is 39% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current OCF Yield % is 4.92, which is 23% below median its own 10-year median of 6.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current OCF Yield % is 4.92, which is 23% below median its 10-year median of 6.41 and 39% above the Drug Manufacturers industry median of 3.54. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current OCF Yield % is 4.92 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
OCF Yield %: 4.92 (23% below median its 10-year median of 6.41)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 39% above the Drug Manufacturers median (#422 of 1005)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
